Pharmacologic and Surgical Retreatment After Office-based Treatments for Benign Prostatic Hyperplasia: A Systematic Review

Baboudjian, Michael; Cornu, Jean‐Nicolas; Gondran-Tellier, Bastien; Fourmarier, M.; Robert, G.; Peyronnet, B.; Misraï, Vincent; Pradère, Benjamin

doi:10.1016/j.euf.2023.03.004

Cited by 6 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even pharmacologic re-treatments are poorly reported, with up to 7% after 3 years for iTIND and up to 11% after 5 years of follow-up for WVTT and PUL. 63 Only one real-world experience with WVTT could be considered of good quality, and even though the follow-up is short (16.7 months), the authors report a re-treatment rate of 4.6%. 64 …”

Section: Evidence Synthesis and Guideline Recommendationsmentioning

confidence: 97%

Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?

Busetto,

Checchia,

Recchia

et al. 2023

Asian Journal of Andrology

View full text Add to dashboard Cite

The increasing importance of treatment of lower urinary tract symptoms (LUTS), while avoiding side effects and maintaining sexual function, has allowed for the development of minimally invasive surgical therapies (MISTs). Recently, the European Association of Urology guidelines reported a paradigm shift from the management of benign prostatic hyperplasia (BPH) to the management of nonneurogenic male LUTS. The aim of the present review was to evaluate the efficacy and safety of the most commonly used MISTs: ablative techniques such as aquablation, prostatic artery embolization, water vapor energy, and transperineal prostate laser ablation, and nonablative techniques such as prostatic urethral lift and temporarily implanted nitinol device (iTIND). MISTs are becoming a new promise, even if clinical trials with longer follow-up are still lacking. Most of them are still under investigation and, to date, only a few options have been given as a recommendation for use. They cannot be considered as standard of care and are not suitable for all patients. Advantages and disadvantages should be underlined, without forgetting our objective: treatment of LUTS and re-treatment avoidance.

show abstract

Section: Evidence Synthesis and Guideline Recommendationsmentioning

confidence: 97%

Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?

Busetto,

Checchia,

Recchia

et al. 2023

Asian Journal of Andrology

View full text Add to dashboard Cite

show abstract

“…Quanto aos tratamentos ambulatoriais para HPB, uma revisão sistemática, conforme discutido no artigo "Retratamento farmacológico e cirúrgico após tratamentos em consultório para hiperplasia prostática benigna: uma revisão sistemática", mostra que esses tratamentos apresentam baixo risco de retratamento, o que apoia sua utilização intermediária na abordagem dos sintomas urinários masculinos (Baboudjian et al, 2023).…”

Section: Artigos Selecionadosunclassified

Avanços no tratamento da Hiperplasia Prostática Benigna: Uma revisão integrativa

Souza,

Sampaio,

Pereira

et al. 2024

RSD

View full text Add to dashboard Cite

A condição conhecida como hiperplasia prostática benigna (HPB) é uma ocorrência comum em homens mais velhos, caracterizada pelo aumento benigno da próstata, que pode levar a sintomas urinários incômodos e afetar significativamente a qualidade de vida. A HPB é uma preocupação de saúde significativa em todo o mundo, afetando a maioria dos homens idosos em maior ou menor grau. Embora não seja uma condição fatal por si só, pode causar complicações graves se não for tratada adequadamente. O tratamento da hiperplasia prostática benigna visa aliviar os sintomas, melhorar a função urinária e reduzir o risco de complicações associadas. Existem várias opções de tratamento disponíveis, que variam de intervenções não invasivas a procedimentos cirúrgicos mais complexos, dependendo da gravidade dos sintomas e das preferências do paciente. Para iniciar o processo de revisão, foi realizada uma busca na base de dados eletrônicas PubMed, com o objetivo de identificar estudos publicados nos últimos 3 anos (2021 a 2024) que abordassem avanços no tratamento da HPB. Os descritores MESH específicos utilizados foram “Benign Prostatic Hyperplasia”, “Treatment”, “Therapeutics”, “Drug therapy”. Esses termos foram selecionados para garantir a inclusão de estudos que abordassem diferentes aspectos relacionados ao tratamento da HPB, desde novas terapias até diretrizes de manejo e previsões para o futuro. Os resultados desta revisão destacam a eficácia de intervenções não invasivas, como modificações no estilo de vida e terapias medicamentosas, na melhoria dos sintomas urinários e na qualidade de vida dos pacientes com HPB leve a moderada.

show abstract

“…Other procedures such as PAE and transurethral microwave thermotherapy (TUMT) were reported to have a higher risk of retreatment (8,9). Recently, a systematic review also summarized the pharmacologic and surgical retreatment rates after newer officebased treatments, including water vapor thermal therapy (WVTT), prostatic urethral lift (PUL), and that using a temporarily implanted nitinol device (iTIND) (10). However, there is still a limited number of reviews on the reoperation rate of common surgeries recommended by the guidelines.…”

Section: Introductionmentioning

confidence: 99%

Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review

He,

Ding,

Niu

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

ContextSurgical treatment is important for male lower urinary tract symptom (LUTS) management, but there are few reviews of the risks of reoperation.ObjectiveTo systematically evaluate the current evidence regarding the reoperation rates of surgical treatment for LUTS in accordance with current recommendations and guidelines.Evidence acquisitionEligible studies published up to July 2023, were searched for in the PubMed® (National Library of Medicine, Bethesda, MD, USA), Embase® (Elsevier, Amsterdam, the Netherlands), and Web of Science™ (Clarivate™, Philadelphia, PA, USA) databases. STATA® (StataCorp LP, College Station, TX, USA) software was used to conduct the meta-analysis. Random-effects models were used to calculate the pooled incidences (PIs) of reoperation and the 95% confidence intervals (CIs).Evidence synthesisA total of 119 studies with 130,106 patients were included. The reoperation rate of transurethral resection of the prostate (TURP) at 1, 2, 3, and 5 years was 4.0%, 5.0%, 6.0%, and 7.7%, respectively. The reoperation rate of plasma kinetic loop resection of the prostate (PKRP) at 1, 2, 3, and 5 years was 3.5%, 3.6%, 5.7%, and 6.6%, respectively. The reoperation rate of holmium laser enucleation of the prostate (HoLEP) at 1, 2, 3, and 5 years was 2.4%, 3.3%, 5.4%, and 6.6%, respectively. The reoperation rate of photoselective vaporization of the prostate (PVP) at 1, 2, 3, and 5 years was 3.3%, 4.1%, 6.7%, and 7.1%, respectively. The reoperation rate of surgery with AquaBeam® at 1, 2, 3, and 5 years was 2.6%, 3.1%, 3.0%, and 4.1%, respectively. The reoperation rate of prostatic artery embolization (PAE) at 1, 2, 3, and 5 years was 12.2%, 20.0%, 26.4%, and 23.8%, respectively. The reoperation rate of transurethral microwave thermotherapy (TUMT) at 1, 2, 3, and 5 years was 9.9%, 19.9%, 23.3%, and 31.2%, respectively. The reoperation rate of transurethral incision of the prostate (TUIP) at 5 years was 13.4%. The reoperation rate of open prostatectomy (OP) at 1 and 5 years was 1.3% and 4.4%, respectively. The reoperation rate of thulium laser enucleation of the prostate (ThuLEP) at 1, 2, and 5 years was 3.7%, 7.7%, and 8.4%, respectively.ConclusionOur results summarized the reoperation rates of 10 surgical procedures over follow-up durations of 1, 2, 3, and 5 years, which could provide reference for urologists and LUTS patients.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD42023445780.

show abstract

Pharmacologic and Surgical Retreatment After Office-based Treatments for Benign Prostatic Hyperplasia: A Systematic Review

Cited by 6 publications

References 43 publications

Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?

Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?

Avanços no tratamento da Hiperplasia Prostática Benigna: Uma revisão integrativa

Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review

Contact Info

Product

Resources

About